SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who started this subject1/15/2001 11:15:04 AM
From: nigel bates   of 1022
 
Jan. 15 /PRNewswire/ -- Cambridge Antibody Technology (LSE: CAT) has announced that it has been granted another US patent, US 6,172,197, entitled ``Methods for Producing Members of Specific Binding Pairs.''
The patent provides protection for libraries of phage displaying functional protein binding domains derived from natural repertoires of nucleic acids, wherein each phage particle contains a phagemid genome. Dependent claims cover display of antibodies, and of scFv or Fab antibody fragments.
Dr. David Chiswell, CAT's CEO, commented, ``This patent further extends CAT's growing US patent estate covering the phage display of antibodies and antibody fragments. It is particularly noteworthy that this new patent includes not just scFv antibody fragments but also Fab antibody fragments as well as other non-antibody proteins. Taken together with CAT's other patents granted worldwide, the granting of this patent reinforces the strength of CAT's patent position and confirms CAT's leadership in the development of human antibodies.''
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News